Joint ERS/EACTS/ESTS clinical practice guidelines on adults with spontaneous pneumothorax.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
May 2024
Historique:
received: 31 05 2023
accepted: 09 02 2024
medline: 29 5 2024
pubmed: 29 5 2024
entrez: 28 5 2024
Statut: epublish

Résumé

The optimal management for spontaneous pneumothorax (SP) remains contentious, with various proposed approaches. This joint clinical practice guideline from the ERS, EACTS and ESTS societies provides evidence-based recommendations for the management of SP. This multidisciplinary Task Force addressed 12 key clinical questions on the management of pneumothorax, using ERS methodology for guideline development. Systematic searches were performed in MEDLINE and Embase. Evidence was synthesised by conducting meta-analyses, if possible, or narratively. Certainty of evidence was rated with GRADE (Grading of Recommendations, Assessment, Development and Evaluations). The Evidence to Decision framework was used to decide on the direction and strength of the recommendations. The panel makes a conditional recommendation for conservative care of minimally symptomatic patients with primary spontaneous pneumothorax (PSP) who are clinically stable. We make a strong recommendation for needle aspiration over chest tube drain for initial PSP treatment. We make a conditional recommendation for ambulatory management for initial PSP treatment. We make a conditional recommendation for early surgical intervention for the initial treatment of PSP in patients who prioritise recurrence prevention. The panel makes a conditional recommendation for autologous blood patch in secondary SP patients with persistent air leak (PAL). The panel could not make recommendations for other interventions, including bronchial valves, suction, pleurodesis in addition to surgical resection or type of surgical pleurodesis. With this international guideline, the ERS, EACTS and ESTS societies provide clinical practice recommendations for SP management. We highlight evidence gaps for the management of PAL and recurrence prevention, with research recommendations made.

Sections du résumé

BACKGROUND BACKGROUND
The optimal management for spontaneous pneumothorax (SP) remains contentious, with various proposed approaches. This joint clinical practice guideline from the ERS, EACTS and ESTS societies provides evidence-based recommendations for the management of SP.
METHODS METHODS
This multidisciplinary Task Force addressed 12 key clinical questions on the management of pneumothorax, using ERS methodology for guideline development. Systematic searches were performed in MEDLINE and Embase. Evidence was synthesised by conducting meta-analyses, if possible, or narratively. Certainty of evidence was rated with GRADE (Grading of Recommendations, Assessment, Development and Evaluations). The Evidence to Decision framework was used to decide on the direction and strength of the recommendations.
RESULTS RESULTS
The panel makes a conditional recommendation for conservative care of minimally symptomatic patients with primary spontaneous pneumothorax (PSP) who are clinically stable. We make a strong recommendation for needle aspiration over chest tube drain for initial PSP treatment. We make a conditional recommendation for ambulatory management for initial PSP treatment. We make a conditional recommendation for early surgical intervention for the initial treatment of PSP in patients who prioritise recurrence prevention. The panel makes a conditional recommendation for autologous blood patch in secondary SP patients with persistent air leak (PAL). The panel could not make recommendations for other interventions, including bronchial valves, suction, pleurodesis in addition to surgical resection or type of surgical pleurodesis.
CONCLUSIONS CONCLUSIONS
With this international guideline, the ERS, EACTS and ESTS societies provide clinical practice recommendations for SP management. We highlight evidence gaps for the management of PAL and recurrence prevention, with research recommendations made.

Identifiants

pubmed: 38806203
pii: 13993003.00797-2023
doi: 10.1183/13993003.00797-2023
pii:
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article has been co-published with permission in the European Journal of Cardio-Thoracic Surgery and in the European Respiratory Journal. Copyright ©The Author(s) 2024. Published by European Respiratory Society. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article. For reproduction rights and permissions contact permissions@ersnet.org.

Déclaration de conflit d'intérêts

Conflict of interest: R. Hallifax has received consulting fees from Rocket Medical UK and Cook Medical, and honoraria for educational talks from AstraZeneca. M. Keijzers has received consulting fees from Philips. Y.C.G. Lee received drainage kits from Rocket Medical PLC for patients participating in clinical trials. P. Licht has received personal honoraria from Ethicon and Johnson & Johnson. N. Maskell has received consulting fees and device support for clinical trials from Rocket Medical UK and BD. B. Nagavci acted as ERS methodologist. E. Roessner has received consultancy fees from Rivolution, lecture fees from Siemens Healthineers and AstraZeneca, and was Thoracic Domain chair, Council member and Task Force member of the Solitary Pulmonary Nodules Task Force for EACTS. N. Rahman has received consulting fees Rocket Medical UK and Cook Medical, and has received device support for clinical trials from Rocket Medical UK. P. Van Schil has received personal payments from BMS and Roche, institutional payment from Janssen, MSD and AstraZeneca, and is the treasurer of BACTS (Belgian Association for Cardiothoracic Surgery) and president-elect for IASLC (International Association for the Study of Lung Cancer). D. Waller has received lecture fees from Pulmonx and Medtronic. T. Walles has received a grant (WA 1649/5-2) for clinical study on surgical therapy for treatment of primary pneumothorax from the German Research Foundation, and is an assessor (unpaid) for the German Society of Thoracic Surgery. The remaining authors have no potential conflicts of interest to disclose.

Auteurs

Steven Walker (S)

Academic Respiratory Unit, Southmead Hospital, Bristol, UK steven.walker@bristol.ac.uk.
Junior Chair of the Task Force.

Robert Hallifax (R)

Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.

Sara Ricciardi (S)

Unit of Thoracic Surgery, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Deirdre Fitzgerald (D)

Pleural Medicine Unit, Institute for Respiratory Health, Perth, Australia.
Medical School and Centre for Respiratory Health, University of Western Australia, Perth, Australia.

Marlies Keijzers (M)

Department of Surgery, Maxima Medical Center, Veldhoven, The Netherlands.

Olivia Lauk (O)

Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.

Jesper Petersen (J)

Respiratory Research Unit PLUZ, Department of Respiratory Medicine Zealand, University Hospital, Naestved, Denmark.

Luca Bertolaccini (L)

Division of Thoracic Surgery IEO, European Institute of Oncology IRCCS, Milan, Italy.

Uffe Bodtger (U)

Respiratory Research Unit PLUZ, Department of Respiratory Medicine Zealand, University Hospital, Naestved, Denmark.

Amelia Clive (A)

North Bristol Lung Centre, Southmead Hospital, Bristol, UK.

Stefano Elia (S)

Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.
Thoracic Surgical Oncology Programme, Tor Vergata University Hospital, Rome, Italy.

Marios Froudarakis (M)

Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Medical School, University Jean Monnet, Saint Etienne, France.

Julius Janssen (J)

Department of Pulmonology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.

Y C Gary Lee (YCG)

Pleural Medicine Unit, Institute for Respiratory Health, Perth, Australia.
Medical School and Centre for Respiratory Health, University of Western Australia, Perth, Australia.

Peter Licht (P)

Department of Cardiothoracic Surgery, Odense University Hospital, Odense, Denmark.

Gilbert Massard (G)

Department of Thoracic Surgery, University of Luxembourg, Hôpitaux Robert Schuman, Luxembourg, Luxembourg.

Blin Nagavci (B)

Institute for Evidence in Medicine, University Medical Center Freiburg, Freiburg, Germany.

Jens Neudecker (J)

Competence Center for Thoracic Surgery, Charité - Universitätsmedizin, Berlin, Germany.
Department of Surgery, Campus Charité Mitte, Campus Virchow-Klinikum, Berlin, Germany.

Eric Roessner (E)

Department of Thoracic Surgery, Center for Thoracic Diseases, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Paul Van Schil (P)

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.

David Waller (D)

Thorax Centre, St Bartholomew's Hospital, London, UK.

Thorsten Walles (T)

Clinic for Cardiac and Thoracic Surgery, Magdeburg University Hospital, Magdeburg, Germany.

Giuseppe Cardillo (G)

Unit of Thoracic Surgery, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy.
Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Unicamillus - International University of Health Sciences, Rome, Italy.
Senior Chairs of the Task Force.

Nick Maskell (N)

Academic Respiratory Unit, Southmead Hospital, Bristol, UK.
North Bristol Lung Centre, Southmead Hospital, Bristol, UK.
Senior Chairs of the Task Force.

Najib Rahman (N)

Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford, UK.
Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
Oxford NIHR Biomedical Research Centre, Oxford, UK.
Chinese Academy of Medical Sciences Oxford Institute, Oxford, UK.
Senior Chairs of the Task Force.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH